Search Results

Neurelis, Inc. will present a poster on VALTOCO® (diazepam nasal spray) for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in patients with epilepsy ages 6 to 65 years, describing the time to treatment across different subpopulations.

April 11, 2024

·

8 min read

Biotech Beach

NEURELIS ANNOUNCES PRESENTATIONS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

Neurelis, Inc., today announced that the company will present six poster presentations at the American Epilepsy Society (AES) Annual Meeting held in Orlando, Florida from December 1 – 5, 2023.

December 1, 2023

·

11 min read

Biotech Beach

Neurelis to Host Virtual Pipeline Update to Discuss Advancements Addressing Unmet Needs in Neuroscience on March 7, 2024

Neurelis, Inc., today announced it will host an investor call to highlight updates on two of its neuroscience product development candidates, The investor call will be held virtually on Thursday, March 7, 2024 at 10:30 AM ET.

February 26, 2024

·

6 min read

Biotech Beach

Neurelis, Inc. to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Neurelis, Inc., a company focused on epilepsy and orphan neurologic disorders, today announced that corporate leadership will participate in and host one-on-one investor meetings at the 6th Annual Evercore ISI HealthCONx Conference, to be held in Miami from November 28-30, 2023.

November 16, 2023

·

1 min read